Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants

NCT04049760 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT04049760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04049760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants
Lead sponsor
Amicus Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
October 11, 2019
Completion date
November 29, 2024
Enrollment
16 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease